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Purpose: This essay reviews the experimental treatments and new imaging modalities that 
are currently being explored by investigators to help treat patients with age-related macular 
degeneration (AMD).
Design: Interpretative essay.
Methods: Literature review and interpretation.
Results: Experimental treatments to preserve vision in patients with exudative AMD include 
blocking vascular endothelial growth factor (VEGF), binding VEGF, and modulating the VEGF 
receptors. Investigators are also attempting to block signal transduction with receptor tyrosine 
kinase inhibitors. Experimental treatments for non-exudative AMD include agents that target 
inﬂ  ammation, oxidative stress, and implement immune-modulation. The effectiveness of these 
newer pharmacologic agents has the potential to grow exponentially when used in combination 
with new and improved imaging modalities that can help identify disease earlier and follow 
treatment response more precisely.
Conclusion: With a better understanding, at the genetic and molecular level, of AMD and the 
development of superior imaging modalities, investigators are able to offer treatment options 
that may offer unprecedented visual gains while reducing the need for repetitive treatments.
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Introduction
Etiological research suggests that age-related macular degeneration (AMD) is a 
complex disease caused by the interaction of environmental factors and genetic pre-
disposition.1 Though dramatic advances have been made in AMD comprehension and 
therapeutics, critical issues remain to be addressed. How do we select patients that 
are most likely to respond to treatment? What will be the local or long-term effect of 
anti-VEGF therapies regarding side effects and resistance?2,3 Is it possible to reduce 
the frequency of intra-vitreal injections by combining therapies? Is it possible to target 
other angiogenic molecules?
In this review we will explore the experimental pharmocological agents, new 
imaging modalities, and genetic advances in AMD that are on the horizon that may 
help answer some of these questions.
Experimental treatments in exudative AMD
Angiogenesis is a complex multi-step process regulated by a balance between positive 
and negative factors. In numerous studies, vascular endothelial growth factor (VEGF) 
has been implicated as an essential potent positive regulatory factor in angiogenesis.2 
There are, however, many other positive factors in angiogenesis including ﬁ  broblast 
growth factors, angiopoietins, TGF-a and -b, hepatocyte growth factors, connective 
tissue growth factors, and IL-8. Endogenous negative regulatory factors also exist, 
which include thrombospondin, angiostatin, endostatin, and pigment epithelium Clinical Ophthalmology 2009:3 168
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derived factor (PEDF).4 Moreover, recent information 
supports that the decline of the ocular down-regulatory 
immune environment plays an important role in AMD, and 
it is suggested that immunotherapy could positively alter the 
course of the disease.5
VEGF pathway
Blocking VEGF expression
RNA interference (RNAi) is a new method to inhibit the 
production of VEGF by the post-transcriptional silencing 
of gene expression.6–8 Small interference RNA (si-RNA) 
is a double stranded RNA (ds-RNA) consisting of 21 to 
22 nucleotides which is incorporated into the cell. Small 
interference RNA silences the expression of a protein 
in a specific and potent fashion by utilizing ds-RNA 
molecules that target a particular messenger RNA (mRNA). 
The advantage of RNAi over anti-sense and ribozyme is 
the ability of RNAi to amplify the destruction of mRNA 
by activating a protein complex called RNA-induced 
silencing complex (RISC). Unlike single stranded anti-sense 
RNA, RISC uses the ds-RNA sequence to seek and 
destroy homologous mRNA in a multiple turnover kinetic 
fashion.9,10 One ds-RNA can destroy hundreds of targeted 
mRNA (cleaved and then digested), which will result in the 
silencing of thousands of molecules.11 It has been shown 
that si-RNA against VEGF is a potent strategy for inhibiting 
growth and leakage of CNV in neovascular AMD.12–14 Small 
interference RNA down regulates the VEGF production (by 
post-transcriptional gene silencing) but has no effect on the 
VEGF already produced and may explain why its effective-
ness is often delayed. Nevertheless, siRNA is a promising 
treatment for consequent and long-acting blockage of the 
VEGF. A phase II study (C.A.R.E), a randomized, double-
masked, controlled, dose comparison of bevasiranib 
(formerly Cand5) for the treatment of neovascular CNV, in 
which 3 doses (0.2 mg, 1.5 mg, 3 mg) were administered by 
2 injections, 6 weeks apart, to 127 subjects has been con-
ducted. Approximately 78% of subjects lost 15 letters at 
the 12-week endpoint. An initial worsening of visual acuity 
and increase in CNV size followed by a reversal of both 
parameters in the second month suggest that bevasiranib is 
able to turn off VEGF production for prolonged periods but 
that the clinical effect is not seen until after all the VEGF 
already present in the eye has been cleared. No adverse 
effects, local or general, were described except one case 
of transient vitritis (within the 3 mg group). Future studies 
incorporating initial neutralization of VEGF with anti-VEGF 
agents are planned.15
Binding VEGF
The successful application of anti-VEGF approaches in the 
clinic is obviously a turning point in AMD. Three different 
molecules described previously (pegaptanib, ranibizumab, 
and bevacizumab) bind VEGF and induce inhibition 
of CNV.
Another option is to bind and inhibit VEGF by using 
VEGF Trap. It is a recombinant soluble VEGF receptor pro-
tein in which the binding domains of VEGF receptors one and 
two are combined with the Fc portion of immunoglobulin G. 
The receptor portion of the molecule has a very high afﬁ  nity 
for all types of VEGF (VEGF-A, -B, -C, -D, and PGF). 
VEGF Trap presents a high potency for neutralizing all forms 
of VEGF. The VEGF Trap continues to have a persistent 
effect even at low concentration since its bulky Fc portion 
allows it to clear from the body slowly. It offers a longer 
interim between injections without losing its efﬁ  cacy.16 
The efﬁ  cacy of VEGF Trap in the suppression of CNV has 
been shown in multiple studies.17 A phase I trial assessing 
the safety, pharmacokinetics, and biological activity of intra-
venous administration of VEGF Trap in neovascular AMD 
subjects has been conducted.18 It showed that the VEGF 
Trap inhibited the growth of new blood vessels when given 
intravenously, as well as when administered directly into 
the eye. The maximum tolerated dose of iv VEGF Trap in 
the study was 1 mg/kg. This dose resulted in elimination of 
approximately 60% of the excess retinal thickness after either 
single or multiple administrations. The side effects described 
were moderate in severity and included hypertension and 
proteinuria but no thrombo-embolic events.
Modulating VEGF receptors
Vascular endothelial growth factor receptor 1 and mainly 
VEGF-R2 are considered to be important in the VEGF 
angiogenic cascade in neovascular AMD.19 Vascular 
endothelial growth factor receptors can be inhibited in two 
ways. One can use siRNA (described previously) directed 
against VEGF receptor mRNA or a chimeric protein of 
VEGF coupled to a toxin.
A siRNA technique, called Sirna-027, targeted to 
VEGF-R1 mRNA, was found to be effective in different 
animal models in reducing choroidal and retinal neovascu-
larization. A phase I clinical trial including 14 subjects with 
neovascular AMD showed that the drug was well tolerated 
and induced a reduction in retinal thickness in 6 of the 
7 subjects studied.20 These data suggest that VEGF-R1 plays 
an important role in the development CNV and that targeting 
VEGF-R1 mRNA with si-RNA has therapeutic potential.21Clinical Ophthalmology 2009:3 169
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The administration of a chimeric protein consisting 
of VEGF 121 coupled to the toxin gelonin (VEGF/rGel) 
has been tested in mice. After intravenous injection of 
45 mg/kg VEGF/rGel, there was immuno-fluorescent 
staining for rGel within choroidal neovascularization and 
regression of the neovascularization occurred in the mice, 
demonstrating successful vascular targeting via the systemic 
circulation. The strategy of vascular targeting can be applied 
to non-malignant neovascular diseases and could serve as 
the basis for new treatments to reduce established ocular 
neovascularization.22
Blocking VEGF signal transduction
Vascular endothelial growth factor signals through two 
tyrosine kinase receptors, Flt 1 (VEGFR1) and KDR 
(VEGFR2, Flk-1). New classes of drugs called receptor 
tyrosine kinase inhibitors are ATP-competitive inhibitors, 
and they can block the receptor for tyrosine kinases, including 
all VEGF receptors as well as the PDGF receptors.23–25 
The assessment of a KDR (VEGFR2) kinase inhibitor in 
two well-established models of ocular neovasculariza-
tion following oral administration has been described.26 
At doses of 100 mg/kg, the KDR kinase inhibitor resulted in 
a 98% reduction in lesion size in the rat CNV model. Doses 
of 30 mg/kg of the inhibitor showed a 70% reduction in 
lesion size in the laser-induced CNV model. The researchers 
concluded that the oral dosing of the described KDR kinase 
inhibitor effectively inhibits ocular neovascularization 
in animal models. Another study evaluated the SU11248 
(multi-targeted receptor tyrosine kinase inhibitor) on murine 
CNV models, which showed that oral administration of this 
compound is potentially beneﬁ  cial in treating CNV caused 
by AMD.27 A phase III study evaluating the same product 
in oncology showed that it was well tolerated in humans. 
A randomized, masked, single and multiple-dose, sequential 
dose-escalation phase I–II study of AG-013958 (another 
receptor tyrosine kinase inhibitor) in neovascular AMD was 
halted in July 2006, as the drug was not providing the antici-
pated results. A phase II study evaluating another VEGFR 
tyrosine kinase inhibitor (vatalanib) started in July 2007.
Inhibition of intracellular effects of VEGF
Steroids have angiostatic effects in animal models of CNV 
but present side effects because of their mineral and gluco-
corticoid activities (high intraocular pressure and cataract 
formation). A new class of angiostatic agents, derived from 
a steroid called cortisene, has been developed. Anecortave 
acetate (Retaane®) can inhibit angiogenesis in animal models. 
Anecortave acetate affects the angiogenic proteolytic cascade 
at multiple levels. It can partially suppress the urokinase 
activator and pro-matrix metalloproteinase expression and 
inhibit VEGF expression and insulin-like growth factor-1. 
It has been evaluated in many studies alone and in combina-
tion with other therapies.28–30 In the monotherapy trial, the 
administration of 15 mg by a posterior juxta-scleral depot 
at 6-month intervals resulted in signiﬁ  cant beneﬁ  ts (visual 
acuity stabilization and prevention of severe vision loss) in 
comparison with placebo.31 A phase III study comparing 
anecortave acetate 15 mg to vPDT for maintaining vision in 
subjects with predominantly classic choroidal neovascular-
ization failed to demonstrate non-inferiority of anecortave 
acetate to vPDT.32 The study did show that anecortave acetate 
at 15 mg was safe and well tolerated in the overall subject 
population. Anecortave acetate is currently being tested 
(AART study) as a preventive agent in intermediate AMD 
subjects who are at risk of progressing to exudative AMD.
Counteracting VEGF
Several endogenous physiological inhibitors of angiogenesis 
have been identiﬁ  ed and include fragments of matrix com-
ponents, endostatins, angiostatins, and pigment epithelium-
derived factor (PEDF).33–35 Pigment epithelium-derived factor 
is normally produced in the eye and serves two important 
functions: to regulate normal blood vessel growth and to 
protect the photoreceptors. Pigment epithelium-derived 
factor also inhibits endothelial cell migration in vitro and 
is signiﬁ  cantly decreased in eyes that harbor AMD. It has 
been shown that adenoviral-mediated intraocular delivery 
of PEDF reduces CNV formation.36,37 Ad-PEDF is an intra-
vitreal or peri-ocular injected transgene which uses a DNA 
carrier (virus vector) to deliver the PEDF gene, resulting 
in the local production of PEDF in the treated eye. A dose 
escalation phase I, multi-center clinical trial including 
28 subjects with neovascular AMD showed no dose-limiting 
toxicity or adverse effects. Other gene therapies evaluated in 
animal studies demonstrated their potential in the treatment 
of CNV. Short hairpin (sh) RNA, which targets VEGF from 
adenovirus vectors, allows potent attenuation of VEGF 
and prevents CNV.38 Another gene delivery angiogenesis 
inhibitor, vasostatin, has been tested and shown to reduce 
the size of the CNV lesion.39
Other anti-angiogenic strategies 
(non-VEGF related)
The turnover of the new drugs assessed in exudative AMD is 
fast. Studies of drugs such as combretastatin A-4 phosphate Clinical Ophthalmology 2009:3 170
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(a structural analog to colchicines) and squalamine lactate 
(broad spectrum aminosterol antibiotic isolated from the 
cartilage of the dogﬁ  sh shark), which were considered very 
promising a few months ago were recently stopped.40–42
Given the role of the immune system in AMD, new 
strategies addressing these mechanisms, both systemic and 
local, alone or in combination with anti-VEGF drugs, seem 
to be appropriate.5 In that way, new drugs such as inﬂ  iximab 
(Remicade®) (directed against TNF axis), rapamycin 
(anti-angiogenic and anti-immune properties), and daclizumab 
(antibody directed against IL-2 receptor) are being tested. 
Other areas of research are at the preliminary stages of human 
development.43 New blood vessels in postnatal events are 
related to angiogenesis but also to vasculogenesis, which 
corresponds to the recruitment and differentiation of bone 
marrow derived angioblasts (endothelial progenitor cells or 
EPC into mature endothelial cells).44 Inﬂ  ammation, through 
macrophages, also appears to play an important role in the 
angiogenic cascade.45 Proteases (plasmin and MMPs) play 
an important role in tissue remodeling and cell recruitment 
associated with pathological angiogenesis and should also be 
carefully explored.46
Experimental treatments 
in atrophic AMD
Even though the atrophic form of AMD represents 90% of 
all cases of AMD, there is no effective treatment available. 
New approaches are now being considered to prevent atrophic 
AMD, since we now have a better understanding of the patho-
logical processes involved. Atrophic AMD is a neurodegen-
erative disease of the retina. The retinal pigment epithelium 
(RPE) seems to be the target of inﬂ  ammation, oxidative stress, 
and possibly accumulation of lipofuscin and prevention of 
these factors may delay the progression of AMD.47
Targeting oxidative stress
Oxidative stress of the RPE and photoreceptors play a major 
role in the development of AMD. The AREDS study data have 
shown a preventive effect of antioxidant therapy in delaying 
the progression of atrophic AMD. It is thought that a more 
powerful antioxidant cocktail including free radical scaven-
gers, catalytic mimetics, and inhibitors of ROS-generating 
enzymes as well as metal chelators may have better efﬁ  cacy 
in preventing the progression of AMD.
Targeting inﬂ  ammation
The critical role of inﬂ  ammation in the pathophysiology of 
atrophic AMD has been established by the recent discovery 
regarding the association of complement factor H mutations 
with AMD. The factor H mutation is responsible of the 
increased activation of the alternative complement pathway. 
A potent inhibitor of the alternative pathway may have an 
effective role as an anti-AMD treatment. A new potent 
inhibitor of complement factor C3, POT-4, was assessed in 
a preclinical safety study of intra-vitreal and systemic admin-
istration in cynomologus monkeys. No local or systemic 
toxicity of POT-4 was described. A phase II evaluation was 
to start in 2008.32
Immune-modulation
The reactive gliosis via the Muller cells is involved in impairing 
vision in the atrophic forms of AMD. A down-regulation 
of reactive gliosis may represent a new therapeutic area. 
Copaxone® is a new immuno-modulatory therapy currently 
tested in a prospective, randomized, double-masked, sham-
controlled pilot study. At 12 weeks, the eyes treated with 
Copaxone showed a reduction of 66% of the drusen versus 
0.6% in the sham group. These preliminary results showed 
that Copaxone might have the potential to reduce drusen and 
prevent the evolution toward atrophic AMD.48
Cell replacement strategy is a treatment venue currently 
being explored. The autologous transplantation of retinal stem 
cells may allow photoreceptor regeneration, if the synaptic 
connections between the RPE cells are established.
Experimental treatment 
in end stage AMD
A visual prosthetic implant including a ﬁ  xed-focus telescopic 
system works as a wide-angle and produces a telephoto effect 
that enlarges the objects in a patient’s central visual ﬁ  eld. 
A phase II/III trial including 217 subjects with bilateral end 
stage AMD is ongoing. The results at 1 year show 3 lines 
improvement regarding distance visual acuity in 67% of 
the implanted eyes versus 13% in control eyes. Near vision 
improved in 53% of implanted eyes versus 10% in the 
control eyes. The results were similar at 2 years with a 
mean improvement of 3.2 lines in distance visual acuity and 
2.9 lines in near visual acuity. The main limitation and FDA 
concern regarding this interesting intraocular device is the 
endothelial cell loss due to trauma from the implantation 
procedure (20% at 3 months, 25.3% at 12 months and 27.8% 
at 2 years).49,50
New imaging modalities
Over the past few years imaging modalities have evolved 
signif icantly growing from the body of research that suggests Clinical Ophthalmology 2009:3 171
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current methods of neovascular detection identify pathology 
too late in the course of the disease. Previous studies such as 
TAP, VIP, and others used ﬂ  uorescein angiography (FA) to 
determine the need for treatment, while other studies imple-
mented indocyanine green angiography (ICG). More recent 
pharmaceutical trials are implementing optical coherence 
tomography (OCT), scanning laser ophthalmoscopy (SLO), 
fundus auto-ﬂ  uorescence, and functional imaging such as 
fundus-related micro-perimetry. The use of these newer 
imaging modalities allows for early detecting, identifying 
prognostic predictors, and monitoring treatment response in 
a less invasive way as compared to FA alone.
OCT
Optical coherence tomography (OCT) is a non-contact, 
non-invasive low coherence imaging device that produces 
a high resolution, cross-sectional image of the retina. This 
device has improved the visualization of the vitreo-retinal, 
intra-retinal, and sub-retinal structures and has added to our 
understanding of pathologic processes. The commercially 
available instrument, stratus OCT-3 (Carl Zeiss Meditec, 
Dublin, Cal.), employs a time-domain OCT technique 
that requires long acquisition times and provides axial 
and lateral resolutions on the order of 15 μm. The slow 
speed and relatively low resolution of this system may not 
allow adequate information on some types of neovascular 
complexes. On the other hand, Fourier-domain (also known 
as spectral domain) optical coherence tomography (Fd-OCT 
or SD-OCT) is a new imaging technique that utilizes 
the Fourier transformation to gather depth data from the 
spectra of the OCT signal. The Fd-OCT does not require 
the time for mechanical movement of the scanning mirror 
to obtain depth information, as is required for conventional 
time-domain systems used in clinics today. Fd-OCT has 
increased speed of data collection by a factor 50 ( time domain 
OCT functions at 400 A-scans/sec, while Fd-OCT systems 
scans at ∼20,000 A-scans/sec). The beneﬁ  ts of the Fd-OCT 
imaging are numerous: greater density of sampling and better 
image quality (3 μm axial, 10 μm transverse), covers more 
areas of the retina, decreased patient movement artifact.
Thanks to the new Fd-OCT systems available, high 
resolution B-scan images of the macula can then be 
obtained from the faster acquisition time allowing for 
three-dimensional reconstructions of neovascular complexes. 
It can provide details of the macula that may be missed by 
time-domain OCT-3.
The Spectralis HRA + OCT (Heildelberg, Germany) 
combines spectral domain OCT with laser angiography can 
scan the retina at 40000 scans per second creating highly 
detailed images of retinal structures. Because the OCT and 
FA images are captured simultaneously, physicians can be 
assured of the exact location of the area of interest and can 
correlate the outer visible retina with the internal structure. 
Its advantage comes from the fact that a clinician can look at 
the exact same position in the retina on repeated studies over 
repeated visits. It is also useful to identify small abnormalities 
and be conﬁ  dent that you are actually imaging that particular 
abnormality. The Spectralis can register its cross-sectional 
images to either, FA, ICG, or AF to create an accurate and 
reliable reference point.
Though OCT was initially used for diabetic edema, 
studies have shown that it can help both in the detection 
and classiﬁ  cation of choroidal neovascularization as well as 
determining the need for further follow-up and re-treatment in 
patients with AMD.51–53 It is useful in the initial detection of 
AMD through follow-up and proved effective in detecting the 
presence of sub-retinal and intra-retinal ﬂ  uid, thereby identi-
fying potentially treatable lesions. However, OCT should not 
take the place of FA, but used in conjunction since it could 
not identify the exact components of the lesion.54
OCT can also screen which patients require FA on 
follow-up and help determine the need for re-treatment. 
Fluorescein angiography alone is subject to variability among 
observers and difﬁ  culties in quantifying true leakage, whereas 
OCT combined with FA will increase both the sensitivity and 
speciﬁ  city in determining activity.55 Furthermore, in the era of 
monthly treatments with pharmaco-therapeutic agents, using 
a less invasive imaging modality, such as OCT, is safer, less 
expensive, and more practical for monitoring monthly treatment 
response. Therefore, use of FA in conjunction with OCT will 
likely be the standard of care in the near future.
Fundus auto-ﬂ  uorescence
Fundus auto-ﬂ  uorescence is an imaging modality that has 
the ability to determine the health of the RPE prior to overt 
atrophy. By identifying the build up of lipofuscin accumulating 
within the RPE, it can identify disturbances within the RPE. 
Studies have shown that lipofuscin accumulation may be a 
prognosticating predictor for AMD.56 Other advantages of 
AF imaging, other than being another non-invasive imaging 
system, include its ability the qualitatively evaluate the risk 
of AMD progression by mapping retinal auto-ﬂ  uorescence 
patterns over time.57 However, the reports are limited and 
somewhat conﬂ  icting and further study is warranted. Auto-
ﬂ  uorescence is also useful for mapping GA and has shown 
to be superior to fundus photography or FA in this regard.58 Clinical Ophthalmology 2009:3 172
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Therefore, this imaging modality may be useful for monitoring 
experimental treatments intended to slow down or halt atrophic 
AMD. The current literature, however, consists only of non-
randomized cases series. This was the impetus of The Fundus 
Auto-ﬂ  uorescence in Age-related Macular Degeneration Study 
Group (FAM study group), a multi-center study. The goal 
of the study is to investigate the correlation between fundus 
auto-ﬂ  uorescence and the natural history of AMD and identify 
high-risk auto-ﬂ  uorescence characteristics that can predict 
patients who will progress to late AMD.59
SLO/OCT
Image acquisition in SLO occurs by the use of a narrow 
infrared light directed towards the retina surface. It was 
developed as an alternative to traditional photography with 
FA and offers advantages over traditional FA. Pupillary 
dilation is not mandatory and it can penetrate media.60 
With the recent addition of the OCT to the confocal SLO, 
cross-sectional images can be obtained giving information 
on deep retinal structures. Its applications include the ability 
to image early transit phases to identify feeder vessel when 
used with FA and allows AF imaging to be unaffected by 
anterior segment pathology. In addition, it can allow for 
more precise quantiﬁ  cation of GA to enable us to follow 
treatment response in cases of atrophic AMD. When time 
domain OCT is combined with SLO (SLO/OCT), scans 
can be generated that corresponds pixel-to-pixel to the 
confocal image, allowing for improved registration. This 
allows the treating ophthalmologist to detect small lesions 
with sub-retinal ﬂ  uid that may have been missed with either 
imaging modality alone.
Fundus-related microperimetry
Fundus-related microperimetry is a functional imaging 
system that uses test stimuli that are projected onto the 
retina while the fundus is viewed with an infrared camera. 
A predefined automatic macula test pattern is used 
centered onto the fovea. The light stimuli are presented 
randomly during the examination as in standard static 
perimetry. High-speed image-tracking software of the 
system compensates for eye movements and ensures spatial 
correlation. Functional, micro-perimetric assessment may be 
more important in the follow-up than visual acuity testing 
since it can identify para-foveal scotomas even in eyes with 
preserved visual acuity or areas of visual preservation near a 
complete scotoma. This imaging modality may then be able 
to better quantify subtle change in vision after treatment and 
help guide in patient visual rehabilitation.
Genetics
AMD is a complex disease caused by a combination of 
genetic predisposition and environmental factors. Some 
of the important genes implicated in AMD are as follows. 
The complement factor H (CFH) gene produces a protein 
that inhibits the complement cascade and it is located on 
chromosome 1, the region 1q25–3, and it is associated with 
7.4-fold increase for AMD in individuals homozygous for 
the risk allele. Seddon showed that CFH is related to both 
geographic atrophy and CNV after controlling for other 
environmental risk factors.61 Three loci on chromosome 
10q26, PLEKHA1, LOC387715, and HTRA1 have been 
linked to AMD.62 Jakobsdottir found that SNPrs10490924 
within the 10q26 chromosome, the LOC387715/HTRA1 
confers a population attributable risk of 57%.63 Other genes 
identiﬁ  ed were the adenosine triphosphate binding cassette 
rim protein (ABCR), which has been implicated previously 
in Stargardt’s disease, may account for 3% of AMD cases.64,65 
The CX3CR1 gene located on chromosome 3 is a chemokine 
receptor expressed in retinal cells and has also been impli-
cated in AMD along with mutations in chromosome 6q, 
which is involved in the elongation of very long chain fatty 
acids (EVOVL4).66 Furthermore, mutations in chromosome 
14q, which codes for ﬁ  bulin-5, a protein localized to Bruch’s 
membrane and mutations in chromosome 19q, which codes 
for ApoE, a major transporter of lipids and cholesterol in 
the nervous system have also been implicated in AMD.67 
A number of various factors have already been identiﬁ  ed 
which are involved in the pathogenesis of AMD, and this 
may eventually lead to screening of high risk individuals to 
facilitate and earlier diagnosis and help prevent end stage 
pathology. Though major advances have been made, the 
identiﬁ  cation of genetic factors has not resulted in strate-
gies to modify, halt, or treat the disease thus far. Additional 
studies and trials are warranted.
Conclusion
The complexity of AMD and our limited understanding 
of it, at the molecular level, makes ﬁ  nding effective long-
term treatment options difﬁ  cult. However, over the last few 
years, new research has led to the discovery of various genes 
implicated in its pathogenesis and has allowed investiga-
tors to explore new treatments options that can target the 
disease at various molecular levels. We have reviewed these 
experimental treatments in detail, but only over time and after 
future prospective studies will we be able to evaluate their 
efﬁ  cacy utility. The new and superior imaging modalities 
that are emerging may offer further beneﬁ  ts when combined Clinical Ophthalmology 2009:3 173
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with these experimental treatments by allowing us to follow 
patients more precisely and intervene earlier. The future of 
AMD looks promising, though, as we gain insights into the 
genetic makeup of this intricate disease and begin using 
new treat options in combination with more sophisticated 
imaging devices.
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